Opinion|Videos|August 15, 2024
Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
A panel of medical experts discuss the prevalence and management of poorly controlled rheumatoid arthritis in clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
As we know, many patients do not reach clinical remission and experience uncontrolled disease and progression.
In your practice, how frequently do you see poorly controlled rheumatoid arthritis? How does this prevalence compare with findings in medical literature?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement